Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Niestroj
Andre Niestroj, Sennewitz DE
| Patent application number | Description | Published |
|---|---|---|
| 20090018087 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia. | 01-15-2009 |
André J. Niestroj, Sennewitz DE
| Patent application number | Description | Published |
|---|---|---|
| 20100099721 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Inhibitors of prolyl endopeptidase of formula 1 | 04-22-2010 |
Andre Johannes Niestroj, Sennewitz DE
| Patent application number | Description | Published |
|---|---|---|
| 20080286810 | Use of Inhibtors of Glutaminyl Cyclases for Treatment and Prevention of Disease - Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity. | 11-20-2008 |
| 20090149394 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES - The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o | 06-11-2009 |
| 20100159032 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS - The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof. | 06-24-2010 |
André Johannes Niestroj, Sennweitz DE
| Patent application number | Description | Published |
|---|---|---|
| 20100249149 | Inhibitors of Protein Kinases - are useful as inhibitors of cyclin dependent kinases such as CDK9. | 09-30-2010 |
André Johannes Niestroj, Sennweitz DE
| Patent application number | Description | Published |
|---|---|---|
| 20100249149 | Inhibitors of Protein Kinases - are useful as inhibitors of cyclin dependent kinases such as CDK9. | 09-30-2010 |